Cornelis J M Melief

Author PubWeight™ 136.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009 5.79
2 Dendritic cell immunotherapy: mapping the way. Nat Med 2004 4.28
3 CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003 2.68
4 Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008 2.06
5 Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009 2.04
6 MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic 2009 1.98
7 High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007 1.96
8 Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002 1.93
9 Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004 1.90
10 Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol 2011 1.71
11 Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010 1.67
12 Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002 1.66
13 Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008 1.66
14 Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010 1.59
15 Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009 1.56
16 CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007 1.54
17 Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007 1.53
18 Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol 2002 1.46
19 Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003 1.40
20 Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011 1.39
21 Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005 1.38
22 CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 2002 1.34
23 Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005 1.30
24 Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 2004 1.29
25 Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007 1.28
26 Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010 1.27
27 Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009 1.27
28 Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011 1.26
29 Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 2010 1.24
30 Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007 1.23
31 Therapeutic cancer vaccines. J Clin Invest 2015 1.23
32 New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012 1.23
33 NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008 1.23
34 Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002 1.22
35 Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 2006 1.19
36 Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 2013 1.18
37 Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006 1.17
38 Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 2011 1.16
39 Ins and outs of dendritic cells. Int Arch Allergy Immunol 2006 1.16
40 Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 2008 1.16
41 Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog 2013 1.15
42 Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol 2012 1.14
43 Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007 1.14
44 Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006 1.11
45 Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008 1.11
46 Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008 1.11
47 The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 2004 1.10
48 Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009 1.09
49 Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol 2005 1.09
50 Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011 1.08
51 Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 2003 1.07
52 Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res 2006 1.06
53 Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006 1.05
54 Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012 1.02
55 HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013 1.02
56 C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol 2005 1.01
57 Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res 2008 0.99
58 Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 2006 0.99
59 The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2010 0.98
60 A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 2012 0.97
61 Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 2006 0.96
62 Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013 0.96
63 Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci 2006 0.94
64 Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006 0.94
65 Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol 2013 0.93
66 Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 2005 0.93
67 T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res 2011 0.92
68 Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 2006 0.92
69 Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 2011 0.92
70 Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 2005 0.92
71 CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection. J Virol 2013 0.91
72 Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol 2012 0.91
73 Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 2007 0.90
74 SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 2004 0.90
75 Immunotherapy for persistent viral infections and associated disease. Trends Immunol 2011 0.90
76 Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 2008 0.89
77 The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother 2013 0.89
78 Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 2012 0.89
79 CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. Cancer Res 2005 0.89
80 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorg Med Chem Lett 2009 0.89
81 The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother 2012 0.88
82 Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 2005 0.88
83 Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002 0.88
84 Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 2010 0.88
85 Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 2007 0.88
86 Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2012 0.88
87 Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One 2012 0.87
88 Cancer immunology. Curr Opin Immunol 2011 0.87
89 In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 2002 0.87
90 Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002 0.86
91 Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer 2008 0.85
92 Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J Immunol 2004 0.84
93 Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 2003 0.84
94 Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. J Infect Dis 2010 0.84
95 Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. Eur J Immunol 2012 0.84
96 N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. J Med Chem 2014 0.84
97 Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol 2012 0.84
98 Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol 2008 0.83
99 DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 2013 0.83
100 CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006 0.83
101 Cancer: immune pact with the enemy. Nature 2007 0.83
102 The distinct role of T cell costimulation in antiviral immunity. Curr Opin Virol 2013 0.82
103 Maintenance of immune tolerance depends on normal tissue homeostasis. J Immunol 2005 0.82
104 The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002 0.82
105 Cancer immunology: cat and mouse games. Nature 2005 0.81
106 Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. Hum Immunol 2004 0.81
107 The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med Chem 2014 0.81
108 Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int J Cancer 2003 0.80
109 Competition-based cellular peptide binding assay for HLA class I. Curr Protoc Immunol 2004 0.80
110 Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells. Vaccine 2009 0.80
111 Mutation-specific T cells for immunotherapy of gliomas. N Engl J Med 2015 0.80
112 Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. Bioorg Med Chem Lett 2006 0.79
113 Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 2014 0.79
114 Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002 0.79
115 Revival of the regulatory T cell: new targets for drug development. Drug Discov Today 2004 0.77
116 DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg. Eur J Immunol 2009 0.77
117 Structured reporting of T cell assay results. Cancer Immun 2013 0.77
118 Escort service for cross-priming. Nat Immunol 2005 0.76
119 Conference scene: Immune signatures in the tumor and beyond. Immunotherapy 2012 0.75
120 Safety in numbers. Eur J Hum Genet 2005 0.75
121 Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 2004 0.75
122 Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch Immunol Ther Exp (Warsz) 2002 0.75